We are live on
!
Find out more
VIA
Vident Investment Advisory Portfolio holdings
AUM
$2.9B
1-Year Est. Return
24.67%
This Fund
S&P 500
This Quarter
Est. Return
+8.26%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$2.55B
AUM Growth
+$25.8M
(+1%)
Cap. Flow
-$138M
Cap. Flow
% of AUM
-5.42%
Top 10 Holdings %
Top 10 Hldgs %
14.48%
Holding
1,057
New
159
Increased
342
Reduced
417
Closed
139
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aptiv
APTV
|
+$21.6M |
| 2 |
Illumina
ILMN
|
+$19.5M |
| 3 |
IPG Photonics
IPGP
|
+$12.3M |
| 4 |
NVIDIA
NVDA
|
+$11.2M |
| 5 |
Keurig Dr Pepper
KDP
|
+$7.63M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$36.9M |
| 2 |
IRBT
iRobot
IRBT
|
+$21.3M |
| 3 |
AeroVironment
AVAV
|
+$19.2M |
| 4 |
3D Systems Corp
DDD
|
+$9.45M |
| 5 |
Azenta
AZTA
|
+$9.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.48% |
| 2 | Industrials | 12.8% |
| 3 | Healthcare | 12.25% |
| 4 | Consumer Discretionary | 9.24% |
| 5 | Financials | 5.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
301
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.24M | 0.09% |
47,581
-3,431
| -7% | -$191K |
|
302
MacroGenics
MGNX
$257M
| $2.24M | 0.09% |
104,486
-6,963
| -6% | -$148K |
|
303
Xencor
XNCR
$1.55B
| $2.24M | 0.09% |
57,438
-3,828
| -6% | -$156K |
|
304
Zymeworks
ZYME
$1.67B
| $2.23M | 0.09% |
142,306
-9,485
| -6% | -$136K |
|
305
Archrock
AROC
$5.8B
| $2.21M | 0.09% |
+181,320
| New | +$2.29M |
|
|
MANT
306
DELISTED
Mantech International Corp
MANT
| $2.19M | 0.09% |
34,652
-15,941
| -32% | -$993K |
|
|
MOR
307
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $2.19M | 0.09% |
81,901
-5,872
| -7% | -$176K |
|
308
Nuveen Real Asset Income & Growth Fund
JRI
$352M
| $2.18M | 0.09% |
135,483
+5,535
| +4% | +$90.2K |
|
|
KEM
309
DELISTED
KEMET Corporation
KEM
| $2.16M | 0.08% |
116,578
-62,889
| -35% | -$1.55M |
|
310
Terreno Realty
TRNO
$7.49B
| $2.15M | 0.08% |
57,042
+10,041
| +21% | +$376K |
|
|
UNT
311
DELISTED
UNIT Corporation
UNT
| $2.15M | 0.08% |
82,495
-38,342
| -32% | -$997K |
|
312
Atara Biotherapeutics
ATRA
$76.1M
| $2.13M | 0.08% |
2,060
-137
| -6% | -$134K |
|
|
CLLS
313
Cellectis
CLLS
$285M
| $2.13M | 0.08% |
75,496
-5,031
| -6% | -$145K |
|
|
TWTR
314
DELISTED
Twitter, Inc.
TWTR
| $2.13M | 0.08% |
74,680
-5,190
| -6% | -$184K |
|
|
HA
315
DELISTED
Hawaiian Holdings, Inc.
HA
| $2.11M | 0.08% |
52,680
-9,202
| -15% | -$365K |
|
316
Apogee Enterprises
APOG
$908M
| $2.11M | 0.08% |
+50,964
| New | +$2.46M |
|
317
Skywest
SKYW
$4.34B
| $2.1M | 0.08% |
35,616
-30,193
| -46% | -$1.79M |
|
|
GCI
318
DELISTED
Gannett Co., Inc
GCI
| $2.08M | 0.08% |
208,346
-31,136
| -13% | -$319K |
|
319
Artisan Partners
APAM
$3.02B
| $2.08M | 0.08% |
64,324
-43,384
| -40% | -$1.41M |
|
320
Eaton Vance Tax-Advantaged Dividend Income Fund
EVT
$2.16B
| $2.05M | 0.08% |
83,660
+3,420
| +4% | +$82K |
|
321
Newmont
NEM
$119B
| $2.04M | 0.08% |
67,609
-32,675
| -33% | -$1.11M |
|
322
Arcus Biosciences
RCUS
$3.64B
| $2.04M | 0.08% |
146,384
-9,755
| -6% | -$124K |
|
323
Watsco Inc
WSO
$13.6B
| $2.04M | 0.08% |
11,447
-3,884
| -25% | -$686K |
|
324
Criteo S.A. Ordinary Shares
CRTO
$923M
| $2.04M | 0.08% |
+88,817
| New | +$2.51M |
|
|
CY
325
DELISTED
Cypress Semiconductor
CY
| $2.04M | 0.08% |
+140,461
| New | +$2.31M |
|
Similar funds
EST
TCM
AWS
WI
JP
VCM
FCB
FCFS
Vident Investment Advisory's Q3 2018 Portfolio in Review
As of Q3 2018, Vident Investment Advisory held 1,057 positions worth $2.55B, up 1% from $2.53B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Vident Investment Advisory withdrew a net $138M in Q3 2018, closing 139 positions and reducing 417 holdings. Its most notable exit was Boston Beer, an estimated $5.6M position sold in full.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 27% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Vident Investment Advisory opened a new position in Aptiv worth $19.9M.
- Vident Investment Advisory's largest Q3 2018 buy was Aptiv: 236,834 shares worth $19.9M.
- Vident Investment Advisory added most to Illumina in Q3 2018, an estimated $19.5M increase.
- Vident Investment Advisory's biggest Q3 2018 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $36.9M.
- Vident Investment Advisory fully exited Boston Beer in Q3 2018, selling an estimated $5.6M.
- Vident Investment Advisory's ten largest holdings make up 14% of its $2.55B portfolio in Q3 2018.
- Vident Investment Advisory opened 159 new positions and closed 139 in Q3 2018.
- Vident Investment Advisory's portfolio value rose 1% quarter-over-quarter to $2.55B.
Based on Vident Investment Advisory's 13F filing for Q3 2018, filed 14 Nov 2018.